




RealRate

PHARMACEUTICAL 2020

Iterum Therapeutics plc
Rank 345 of 363



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Iterm Therapeutics plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Iterm Therapeutics plc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 13% points. The greatest weakness of Iterm Therapeutics plc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 105% points.

The company's Economic Capital Ratio, given in the ranking table, is 36%, being 202% points below the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	11,718
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	36,986
Liabilities, Non-Current	15,003
Other Assets	13,461
Other Compr. Net Income	0
Other Expenses	444
Other Liabilities	0
Other Net Income	-665
Other Revenues	37
Property and Equipment	572
Research and Development	90,774
Selling, General and Administrative Expense	11,284

Output Variable	Value in 1000 USD
Assets	25,751
Liabilities	51,989
Expenses	102,502
Revenues	37
Stockholders Equity	-26,238
Net Income	-103,130
Comprehensive Net Income	-103,130
BaseVar	90,472
ECR before LimitedLiability	-412%
Economic Capital Ratio	36%